KeyBanc downgraded Harvard Bioscience (HBIO) to Sector Weight from Overweight. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on HBIO: Harvard Bioscience price target lowered to $4.50 from $5.50 at Benchmark Harvard Bioscience Reports 2024 Financial Results Harvard Bioscience Navigates Growth Amid Challenges Harvard Bioscience reports Q4 adjusted EPS 6c vs. 4c last year Harvard Bioscience sees Q1 revenue $19M-$21M Disclaimer & DisclosureReport an Issue
